Main content area

A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection

Amiram, M., Luginbuhl, K.M., Li, X., Feinglos, M.N., Chilkoti, A.
Journal of controlled release 2013 v.172 no.1 pp. 144-151
adverse effects, blood glucose, body temperature, drugs, glucagon-like peptide 1, half life, mice, noninsulin-dependent diabetes mellitus, phase transition, proteolysis
Peptide drugs are an exciting class of pharmaceuticals for the treatment of a variety of diseases; however, their short half-life dictates multiple and frequent injections causing undesirable side effects. Herein, we describe a novel peptide delivery system that seeks to combine the attractive features of prolonged circulation time with a prolonged release formulation. This system consists of glucagon-like peptide-1, a type-2 diabetes drug fused to a thermally responsive, elastin-like-polypeptide (ELP) that undergoes a soluble–insoluble phase transition between room temperature and body temperature, thereby forming an injectable depot. We synthesized a set of GLP-1-ELP fusions and verified their proteolytic stability and potency in vitro. Significantly, a single injection of depot forming GLP-1-ELP fusions reduced blood glucose levels in mice for up to 5days, 120 times longer than an injection of the native peptide. These findings demonstrate the unique advantages of using ELPs to release peptide-ELP fusions from a depot combined with enhanced systemic circulation to create a tunable peptide delivery system.